NYRADA INC (ASX:NYR) 58 Liquidity risk management Ultimate responsibility for liquidity risk management rests with the Board of Directors, which has established an appropriate liquidity risk management framework for the management of the consolidated entity's short, medium and long-term funding and liquidity management requirements. The Consolidated Entity manages liquidity by maintaining adequate banking facilities, by continuously monitoring forecast and actual cash flows, and by matching the maturity profiles of financial assets and liabilities. Carrying amount Less than 1 month 1-3 months 3-12 months 1 year to 5 years Total contractual cash flows 2024 $ $ $ $ $ $ Trade and other payables 1,481,750 1,390,814 90,934 - - 1,481,748 23. Remuneration of auditors 2025 2024 $ $ Audit and review services William Buck Audit (Vic) Pty Ltd 30,500 43,700 24. Contingent liabilities As at 30 June 2025, the Consolidated Entity had entered into two material agreements relating to the Phase I study of NYR- BI03: • Scientia Clinical Research: A committed balance of $99,051 as at 30 June 2025 • Southern Star Research: A committed balance of $121,793 as at 30 June 2025 These agreements may give rise to additional contingent liabilities due to protocol amendments, adverse events, or other variable trial-related costs.
RkJQdWJsaXNoZXIy MjE2NDg3